Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • RESEARCH HIGHLIGHT

Building on bispecifics

  1. M. Teresa Villanueva
    View author publications

    You can also search for this author in PubMed  Google Scholar

Bispecific molecules that harness immune cells to recognize and eliminate cancer cells are emerging as a promising anticancer drug class. Two new molecules — a bispecific antibody and a bispecific tumour-targeted co-stimulatory agonist — that have enhanced effects in combination with other immunotherapies have recently been reported in Science Translational Medicine.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 18, 582 (2019)

doi: https://doi.org/10.1038/d41573-019-00117-5

References

  1. Crawford, A. et al. A mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci. Transl Med. 11, eaau7534 (2019)

    Article  PubMed  Google Scholar 

  2. Claus, C. et al. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci. Transl Med. 11, eaav5989 (2019)

    Article  PubMed  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links